☆ 4.3 Review

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs

EXPERT REVIEW OF ANTICANCER THERAPY (2010)

Journal

EXPERT REVIEW OF ANTICANCER THERAPY

Volume 10, Issue 1, Pages 81-88

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.1586/ERA.09.165

Keywords

CA-125; chemotherapy; platinum-resistant; platinum-sensitive; recurrent ovarian cancer; targeted therapy

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Most patients with ovarian cancer relapse despite aggressive surgery and platinum-taxane-based primary chemotherapy. Further treatment depends on prior response and progression-free interval. Monotherapy is indicated in patients with so-called platinum-resistant or -refractory ovarian cancer. The standard treatment for patients with platinum-sensitive recurrent ovarian cancer is platinum-based combination chemotherapy. Cytoreductive surgery is also a treatment option in such patients. Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer

Haley A. Moss, Jessica A. Perhanidis, Laura J. Havrilesky, Angeles Alvarez Secord

Summary: The clinical utility of maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer has been validated in several clinical trials. This study analyzed real-world treatment patterns and found that maintenance therapy is becoming more common following 2nd or 3rd line platinum-based chemotherapy, regardless of biomarker status. The use of PARPi is increasing over time, while the use of bevacizumab remains stable.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis

Yuanzhi Liu, Yilan Huang, Jingyan Li, Shengli Wan, Nan Jiang, Jie Yang, Sawitree Chiampanichayakul, Singkome Tima, Songyot Anuchapreeda, Jianming Wu

Summary: This study aimed to find the best treatment plan for patients with platinum-sensitive recurrent ovarian cancer (PSROC) through systematic review and Bayesian network meta-analysis. The results showed that carboplatin plus pegylated liposomal doxorubicin (PLD) plus bevacizumab had the best progression-free survival (PFS) in the initial treatment of PSROC, while carboplatin plus paclitaxel plus bevacizumab had the best overall survival (OS) and objective response rate (ORR). In terms of maintenance therapy, poly (ADP-ribose) polymerase inhibitors (PARPi) following platinum-based chemotherapy provided the best PFS, but had a higher frequency of adverse events.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer A systematic review and meta-analysis

Luting Liu, Wanchun Xiong

Summary: This meta-analysis investigated the efficacy of combining molecular targeted agents (MTAs) with chemotherapy in platinum-resistant recurrent ovarian cancer (ROC) patients. The results showed that this combination therapy significantly increased the objective response rate in patients, but did not lead to improved survival rates. Additionally, it also resulted in a higher occurrence of adverse events and treatment termination.

MEDICINE (2021)

Add to Collection

Article Oncology

A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations

Kazuho Nakanishi, Masafumi Toyoshima, Yuta Ueno, Shunji Suzuki

Summary: This study aimed to determine the optimal maintenance therapy and selection criteria for patients with platinum-sensitive recurrent ovarian cancer (PSROC). The study found that olaparib (Ola) was superior to bevacizumab (Bev) as a maintenance therapy for PSROC patients, with a significantly prolonged recurrence-free survival (RFS) of 27 months in the Ola group compared to 9 months in the Bev group. The efficacy of Ola was independent of background factors, suggesting its superiority in the treatment of PSROC patients, especially in Japanese and Asian populations.

CANCERS (2023)

Add to Collection

Review Oncology

The systemic treatment of recurrent ovarian cancer revisited

T. Baert, A. Ferrero, J. Sehouli, D. M. O'Donnell, A. Gonzalez-Martin, F. Joly, J. van der Velden, P. Blecharz, D. S. P. Tan, D. Querleu, N. Colombo, A. du Bois, J. A. Ledermann

Summary: Treatment approaches for relapsed ovarian cancer have shifted towards patient-oriented biologically driven algorithms. Platinum-based chemotherapy is recommended, while bevacizumab can enhance chemotherapy response and maintenance therapy with a poly(ADP-ribose) polymerase inhibitor may be considered for prolonging efficacy.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Correlation Between Clinical Outcomes and Serum CA-125 Levels After Standard Treatment for Epithelial Ovarian Cancer

Juhun Lee, Jong Mi Kim, Yoon Hee Lee, Gun Oh Chong, Dae Gy Hong

Summary: This study analyzed the relationship between serum CA-125 levels after chemotherapy and clinical outcomes in Korean women with epithelial ovarian cancer. The results showed that serum CA-125 is correlated with clinical outcomes and can be used to predict platinum resistance in ovarian cancer treatment.

ANTICANCER RESEARCH (2022)

Add to Collection

Article Oncology

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer

Panagiotis A. Konstantinopoulos, Jung-Min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer

Summary: This study aimed to evaluate the efficacy and safety of using prexasertib, a CHK1 inhibitor, in treating high-grade serous ovarian cancer. The results showed that prexasertib demonstrated durable single agent activity to a certain extent and its effects were not influenced by clinical characteristics, BRCA status, or prior therapies, including PARPi. The study also emphasized the need for alternative biomarker approaches to identify responders.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Katherine C. Fuh, Michael A. Bookman, Joyce F. Liu, Robert L. Coleman, Thomas J. Herzog, Premal H. Thaker, Bradley J. Monk, Randy Anderson, Gail McIntyre, Reshma Rangwala, Kathleen N. Moore

Summary: AVB-500, a novel high affinity Fc-sAXL fusion protein, combined with chemotherapy showed promising clinical activity in platinum-resistant ovarian cancer (PROC) patients, with no dose limiting toxicities observed.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Article Biochemical Research Methods

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer

Jin Song, Lori J. J. Sokoll, Zhen Zhang, Daniel W. W. Chan

Summary: Close to 75% of ovarian cancer cases are diagnosed at an advanced stage, with a high rate of relapse after primary therapy. Therefore, it is crucial to identify strategies for early detection of ovarian cancer recurrence to improve outcomes.

CLINICAL PROTEOMICS (2023)

Add to Collection

Review Oncology

ATR Inhibitors in Platinum-Resistant Ovarian Cancer

Siyu Li, Tao Wang, Xichang Fei, Mingjun Zhang

Summary: Platinum-resistant ovarian cancer is a deadly cancer with a poor prognosis, and ATR inhibitors have shown promising results in its treatment.

CANCERS (2022)

Add to Collection

Article Multidisciplinary Sciences

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer

Szymon Piatek, Grzegorz Panek, Zbigniew Lewandowski, Dominika Piatek, Przemyslaw Kosinski, Mariusz Bidzinski

Summary: The nadir CA-125 level in patients with epithelial ovarian cancer is associated with progression-free survival but not overall survival. Patients with nadir CA-125 levels between 11-35 U/ml after first-line treatment have a higher risk of recurrence compared to patients with levels <= 10 U/ml.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary studyThe clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study

John K. Chan, Chunqiao Tian, Joshua P. Kesterson, Michael T. Richardson, Ken Lin, Krishnansu S. Tewari, Thomas Herzog, Daniel S. Kapp, Bradley J. Monk, Yovanni Casablanca, Parviz Hanjani, Robert M. Wenham, Joan Walker, Leah McNally, Larry J. Copeland, Sharon Robertson, Samuel Lentz, Nick M. Spirtos, Jeffery G. Bell

Summary: This study aims to investigate the clinical and prognostic significance of CA-125 trends during chemotherapy in high-risk early-stage epithelial ovarian cancer patients. The results showed that normalization of CA-125 after the first cycle of chemotherapy was associated with better survival.

GYNECOLOGIC ONCOLOGY (2022)

Add to Collection

Article Immunology

A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report

Xukai Luo, Yating Sun, Jiajia Li, Qidi Jiang, Lei Yuan, Ting Li, Mo Chen, Liangqing Yao

Summary: This case suggests that ovarian cancer patients with multidrug resistance may still benefit from PD-1 inhibitor therapy, even if PD-L1 pathology is negative.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)

Radoslav Chekerov, Tjadina Arndt, Klaus Pietzner, Ulrich Canzler, Pauline Wimberger, Hans-Georg Strauss, Sven Mahner, Linn Woelber, Nikolaus de Gregorio, Gertraud Stocker, Ekkehard von Abel, Tanja Neunhoeffer, Antje Kristina Belau, Alexander Mustea, Isil Yalinkaya, Elena Ioana Braicu, Rolf Richter, Jalid Sehouli

Summary: This study evaluated the efficacy and safety of combining topotecan with pazopanib in platinum-resistant or intermediate-sensitive recurrent ovarian cancer. The results showed that this combination therapy controlled hematological and liver toxicity, but did not provide a significant survival benefit.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Add to Collection

Review Oncology

Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis

Qingyi Wang, Xiaoling Feng, Xiaofang Liu, Siyu Zhu

Summary: According to the meta-analysis, higher pretreatment serum CA-125 levels are associated with poor prognosis in epithelial ovarian cancer (EOC) patients.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

Suzanne C. Dixon-Suen, Christina M. Nagle, Aaron P. Thrift, Paul D. P. Pharoah, Ailith Ewing, Celeste Leigh Pearce, Wei Zheng, Georgia Chenevix-Trench, Peter A. Fasching, Matthias W. Beckmann, Diether Lambrechts, Ignace Vergote, Sandrina Lambrechts, Els Van Nieuwenhuysen, Mary Anne Rossing, Jennifer A. Doherty, Kristine G. Wicklund, Jenny Chang-Claude, Audrey Y. Jung, Kirsten B. Moysich, Kunle Odunsi, Marc T. Goodman, Lynne R. Wilkens, Pamela J. Thompson, Yurii B. Shvetsov, Thilo Doerk, Tjoung-Won Park-Simon, Peter Hillemanns, Natalia Bogdanova, Ralf Butzow, Heli Nevanlinna, Liisa M. Pelttari, Arto Leminen, Francesmary Modugno, Roberta B. Ness, Robert P. Edwards, Joseph L. Kelley, Florian Heitz, Andreas du Bois, Philipp Harter, Ira Schwaab, Beth Y. Karlan, Jenny Lester, Sandra Orsulic, Bobbie J. Rimel, Susanne K. Kjaer, Estrid Hogdall, Allan Jensen, Ellen L. Goode, Brooke L. Fridley, Julie M. Cunningham, Stacey J. Winham, Graham G. Giles, Fiona Bruinsma, Roger L. Milne, Melissa C. Southey, Michelle A. T. Hildebrandt, Xifeng Wu, Karen H. Lu, Dong Liang, Douglas A. Levine, Maria Bisogna, Joellen M. Schildkraut, Andrew Berchuck, Daniel W. Cramer, Kathryn L. Terry, Elisa V. Bandera, Sara H. Olson, Helga B. Salvesen, Liv Cecilie Vestrheim Thomsen, Reidun K. Kopperud, Line Bjorge, Lambertus A. Kiemeney, Leon F. A. G. Massuger, Tanja Pejovic, Amanda Bruegl, Linda S. Cook, Nhu D. Le, Kenneth D. Swenerton, Angela Brooks-Wilson, Linda E. Kelemen, Jan Lubinski, Tomasz Huzarski, Jacek Gronwald, Janusz Menkiszak, Nicolas Wentzensen, Louise Brinton, Hannah Yang, Jolanta Lissowska, Claus K. Hogdall, Lene Lundvall, Honglin Song, Jonathan P. Tyrer, Ian Campbell, Diana Eccles, James Paul, Rosalind Glasspool, Nadeem Siddiqui, Alice S. Whittemore, Weiva Sieh, Valerie McGuire, Joseph H. Rothstein, Steven A. Narod, Catherine Phelan, Harvey A. Risch, John R. McLaughlin, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Simon A. Gayther, Susan J. Ramus, Aleksandra Gentry-Maharaj, Anna H. Wu, Malcolm C. Pike, Chiu-Chen Tseng, Jolanta Kupryjanczyk, Agnieszka Dansonka-Mieszkowska, Agnieszka Budzilowska, Iwona K. Rzepecka, Penelope M. Webb

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

When should Surgery be used for Recurrent Ovarian Carcinoma?

M. Bommert, P. Harter, F. Heitz, A. du Bois

CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial

Christoph Grimm, Stephan Polterauer, Samir Helmy-Bader, Michal Zikan, David Cibula, Florian Heitz, Philipp Harter, Arnd Giese, Alexander Reinthaller, Clemens Tempfer

GYNECOLOGIC ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility

Madalene Earp, Jonathan P. Tyrer, Stacey J. Winham, Hui-Yi Lin, Ganna Chornokur, Joe Dennis, Katja K. H. Aben, Hoda Anton-Culver, Natalia Antonenkova, Elisa V. Bandera, Yukie T. Bean, Matthias W. Beckmann, Line Bjorge, Natalia Bogdanova, Louise A. Brinton, Angela Brooks-Wilson, Fiona Bruinsma, Clareann H. Bunker, Ralf Butzow, Ian G. Campbell, Karen Carty, Jenny Chang-Claude, Linda S. Cook, Daniel W. Cramer, Julie M. Cunningham, Cezary Cybulski, Agnieszka Dansonka-Mieszkowska, Evelyn Despierre, Jennifer A. Doherty, Thilo Doerk, Andreas du Bois, Matthias Duerst, Douglas F. Easton, Diana M. Eccles, Robert P. Edwards, Arif B. Ekici, Peter A. Fasching, Brooke L. Fridley, Aleksandra Gentry-Maharaj, Graham G. Giles, Rosalind Glasspool, Marc T. Goodman, Jacek Gronwald, Philipp Harter, Alexander Hein, Florian Heitz, Michelle A. T. Hildebrandt, Peter Hillemanns, Claus K. Hogdall, Estrid Hogdall, Satoyo Hosono, Edwin S. Iversen, Anna Jakubowska, Allan Jensen, Bu-Tian Ji, Audrey Y. Jung, Beth Y. Karlan, Melissa Kellar, Lambertus A. Kiemeney, Boon Kiong Lim, Susanne K. Kjaer, Camilla Krakstad, Jolanta Kupryjanczyk, Diether Lambrechts, Sandrina Lambrechts, Nhu D. Le, Shashi Lele, Jenny Lester, Douglas A. Levine, Zheng Li, Dong Liang, Jolanta Lissowska, Karen Lu, Jan Lubinski, Lene Lundvall, Leon F. A. G. Massuger, Keitaro Matsuo, Valerie McGuire, John R. McLaughlin, Iain McNeish, Usha Menon, Roger L. Milne, Francesmary Modugno, Kirsten B. Moysich, Roberta B. Ness, Heli Nevanlinna, Kunle Odunsi, Sara H. Olson, Irene Orlow, Sandra Orsulic, James Paul, Tanja Pejovic, Liisa M. Pelttari, Jenny B. Permuth, Malcolm C. Pike, Elizabeth M. Poole, Barry Rosen, Mary Anne Rossing, Joseph H. Rothstein, Ingo B. Runnebaum, Iwona K. Rzepecka, Eva Schernhammer, Ira Schwaab, Xiao-Ou Shu, Yurii B. Shvetsov, Nadeem Siddiqui, Weiva Sieh, Honglin Song, Melissa C. Southey, Beata Spiewankiewicz, Lara Sucheston-Campbell, Ingvild L. Tangen, Soo-Hwang Teo, Kathryn L. Terry, Pamela J. Thompson, Lotte Thomsen, Shelley S. Tworoger, Anne M. van Altena, Ignace Vergote, Liv Cecilie Vestrheim Thomsen, Robert A. Vierkant, Christine S. Walsh, Shan Wang-Gohrke, Nicolas Wentzensen, Alice S. Whittemore, Kristine G. Wicklund, Lynne R. Wilkens, Yin-Ling Woo, Anna H. Wu, Xifeng Wu, Yong-Bing Xiang, Hannah Yang, Wei Zheng, Argyrios Ziogas, Alice W. Lee, Celeste L. Pearce, Andrew Berchuck, Joellen M. Schildkraut, Susan J. Ramus, Alvaro N. A. Monteiro, Steven A. Narod, Thomas A. Sellers, Simon A. Gayther, Linda E. Kelemen, Georgia Chenevix-Trench, Harvey A. Risch, Paul D. P. Pharoah, Ellen L. Goode, Catherine M. Phelan

PLOS ONE (2018)

Add to Collection

Article Oncology

Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery

Beyhan Ataseven, Teresa Gonzalez Luengo, Andreas du Bois, Kai-Uwe Waltering, Alexander Traut, Florian Heitz, Pier Francesco Alesina, Sonia Prader, Beate Meier, Stephanie Schneider, Jens-Albrecht Koch, Martin Walz, Harald-Thomas Groeben, Pauly Nina, Violeta Brunkhorst, Sebastian Heikaus, Philipp Harter

ANNALS OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

Yingchang Lu, Alicia Beeghly-Fadiel, Lang Wu, Xingyi Guo, Bingshan Li, Joellen M. Schildkraut, Hae Kyung Im, Yian A. Chen, Jennifer B. Permuth, Brett M. Reid, Jamie K. Teer, Kirsten B. Moysich, Irene L. Andrulis, Hoda Anton-Culver, Banu K. Arun, Elisa V. Bandera, Rosa B. Barkardottir, Daniel R. Barnes, Javier Benitez, Line Bjorge, James Brenton, Ralf Butzow, Trinidad Caldes, Maria A. Caligo, Ian Campbell, Jenny Chang-Claude, Kathleen B. M. Claes, Fergus J. Couch, DanielW. Cramer, Mary B. Daly, Anna deFazio, Joe Dennis, Orland Diez, Susan M. Domchek, Thilo Doerk, Douglas F. Easton, Diana M. Eccles, Peter A. Fasching, Renee T. Fortner, George Fountzilas, Eitan Friedman, Patricia A. Ganz, Judy Garber, Graham G. Giles, Andrew K. Godwin, David E. Goldgar, Marc T. Goodman, Mark H. Greene, Jacek Gronwald, Ute Hamann, Florian Heitz, Michelle A. T. Hildebrandt, Claus K. Hogdall, Antoinette Hollestelle, Peter J. Hulick, David G. Huntsman, Evgeny N. Imyanitov, Claudine Isaacs, Anna Jakubowska, Paul James, Beth Y. Karlan, Linda E. Kelemen, Lambertus A. Kiemeney, Susanne K. Kjaer, Ava Kwong, Nhu D. Le, Goska Leslie, Fabienne Lesueur, Douglas A. Levine, Amalia Mattiello, Taymaa May, Lesley McGuffog, Iain A. McNeish, Melissa A. Merritt, Francesmary Modugno, Marco Montagna, Susan L. Neuhausen, Heli Nevanlinna, Finn C. Nielsen, Liene Nikitina-Zake, Robert L. Nussbaum, Kenneth Offit, Edith Olah, Olufunmilayo I. Olopade, Sara H. Olson, Hakan Olsson, Ana Osorio, Sue K. Park, Michael T. Parsons, Petra H. M. Peeters, Tanja Pejovic, Paolo Peterlongo, Catherine M. Phelan, Miquel Angel Pujana, Susan J. Ramus, Gad Rennert, Harvey Risch, Gustavo C. Rodriguez, Cristina Rodriguez-Antona, Isabelle Romieu, Matti A. Rookus, Mary Anne Rossing, Iwona K. Rzepecka, Dale P. Sandler, Rita K. Schmutzler, Veronica W. Setiawan, Priyanka Sharma, Weiva Sieh, Jacques Simard, Christian F. Singer, Honglin Song, Melissa C. Southey, Amanda B. Spurdle, Rebecca Sutphen, Anthony J. Swerdlow, Manuel R. Teixeira, Soo H. Teo, Mads Thomassen, Marc Tischkowitz, Amanda E. Toland, Antonia Trichopoulou, Nadine Tung, Shelley S. Tworoger, Elizabeth J. van Rensburg, Adriaan Vanderstichele, Ana Vega, Digna Velez Edwards, Penelope M. Webb, Jeffrey N. Weitzel, Nicolas Wentzensen, Emily White, Alicja Wolk, Anna H. Wu, Drakoulis Yannoukakos, Kristin K. Zorn, Simon A. Gayther, Antonis C. Antoniou, Andrew Berchuck, Ellen L. Goode, Georgia Chenevix-Trench, Thomas A. Sellers, Paul D. P. Pharoah, Wei Zheng, Jirong Long

CANCER RESEARCH (2018)

Add to Collection

Article Oncology

The genetic landscape of 87 ovarian germ cell tumors

Els Van Nieuwenhuysen, Pieter Busschaert, Patrick Neven, Sileny N. Han, Philippe Moerman, Michalis Liontos, Maria Papaspirou, Jolanta Kupryjanczyk, Claus Hogdall, Estrid Hogdall, Ana Oaknin, Angel Garcia, Sven Mahner, Fabian Trillsch, David Cibula, Florian Heitz, Nicole Concin, Paul Speiser, Helga Salvesen, Jalid Sehouli, Diether Lambrechts, Ignace Vergote

GYNECOLOGIC ONCOLOGY (2018)

Add to Collection

Article Oncology

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

Yaohua Yang, Lang Wu, Xiang Shu, Yingchang Lu, Xiao-Ou Shu, Qiuyin Cai, Alicia Beeghly-Fadiel, Bingshan Li, Fei Ye, Andrew Berchuck, Hoda Anton-Culver, Susana Banerjee, Javier Benitez, Line Bjorge, James D. Brenton, Ralf Butzow, Ian G. Campbell, Jenny Chang-Claude, Kexin Chen, Linda S. Cook, Daniel W. Cramer, Anna defazio, Joe Dennis, Jennifer A. Doherty, Thilo Doerk, Diana M. Eccles, Digna Velez Edwards, Peter A. Fasching, Renee T. Fortner, Simon A. Gayther, Graham G. Giles, Rosalind M. Glasspool, Ellen L. Goode, Marc T. Goodman, Jacek Gronwald, Holly R. Harris, Florian Heitz, Michelle A. Hildebrandt, Estrid Hogdall, Claus K. Hogdall, David G. Huntsman, Siddhartha P. Kar, Beth Y. Karlan, Linda E. Kelemen, Lambertus A. Kiemeney, Susanne K. Kjaer, Anita Koushik, Diether Lambrechts, Nhu D. Le, Douglas A. Levine, Leon F. Massuger, Keitaro Matsuo, Taymaa May, Iain A. McNeish, Usha Menon, Francesmary Modugno, Alvaro N. Monteiro, Patricia G. Moorman, Kirsten B. Moysich, Roberta B. Ness, Heli Nevanlinna, Hakan Olsson, N. Charlotte Onland-Moret, Sue K. Park, James Paul, Celeste L. Pearce, Tanja Pejovic, Catherine M. Phelan, Malcolm C. Pike, Susan J. Ramus, Elio Riboli, Cristina Rodriguez-Antona, Isabelle Romieu, Dale P. Sandler, Joellen M. Schildkraut, Veronica W. Setiawan, Kang Shan, Nadeem Siddiqui, Weiva Sieh, Meir J. Stampfer, Rebecca Sutphen, Anthony J. Swerdlow, Lukasz M. Szafron, Soo Hwang Teo, Shelley S. Tworoger, Jonathan P. Tyrer, Penelope M. Webb, Nicolas Wentzensen, Emily White, Walter C. Willett, Alicja Wolk, Yin Ling Woo, Anna H. Wu, Li Yan, Drakoulis Yannoukakos, Georgia Chenevix-Trench, Thomas A. Sellers, Paul D. P. Pharoah, Wei Zheng, Jirong Long

CANCER RESEARCH (2019)

Add to Collection

Article Oncology

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

F. Heitz, P. Harter, E. Avail-Lundqvist, A. Reuss, P. Pautier, G. Cormio, N. Colombo, A. Reinthaller, I. Vergote, A. Poveda, P. B. Ottevanger, L. C. Hanker, A. Leminen, J. Alexandre, U. Canzler, J. Sehouli, J. Herrstedt, B. Fiane, M. Merger, A. du Bois

GYNECOLOGIC ONCOLOGY (2019)

Add to Collection

Article Oncology

Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer

Sonia Prader, Nils Vollmar, Andreas du Bois, Florian Heitz, Stephanie Schneider, Beyhan Ataseven, Mareike Bommert, Kai-Uwe Waltering, Sebastian Heikaus, Jens Albrecht Koch, Pier Francesco Alesina, Alexander Traut, Philipp Harter

GYNECOLOGIC ONCOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Shared heritability and functional enrichment across six solid cancers

Xia Jiang, Hilary K. Finucane, Fredrick R. Schumacher, Stephanie L. Schmit, Jonathan P. Tyrer, Younghun Han, Kyriaki Michailidou, Corina Lesseur, Karoline B. Kuchenbaecker, Joe Dennis, David V. Conti, Graham Casey, Mia M. Gaudet, Jeroen R. Huyghe, Demetrius Albanes, Melinda C. Aldrich, Angeline S. Andrew, Irene L. Andrulis, Hoda Anton-Culver, Antonis C. Antoniou, Natalia N. Antonenkova, Susanne M. Arnold, Kristan J. Aronson, Banu K. Arun, Elisa V. Bandera, Rosa B. Barkardottir, Daniel R. Barnes, Jyotsna Batra, Matthias W. Beckmann, Javier Benitez, Sara Benlloch, Andrew Berchuck, Sonja I. Berndt, Heike Bickeboeller, Stephanie A. Bien, Carl Blomqvist, Stefania Boccia, Natalia V. Bogdanova, Stig E. Bojesen, Manjeet K. Bolla, Hiltrud Brauch, Hermann Brenner, James D. Brenton, Mark N. Brook, Joan Brunet, Hans Brunnstrom, Daniel D. Buchanan, Barbara Burwinkel, Ralf Butzow, Gabriella Cadoni, Trinidad Caldes, Maria A. Caligo, Ian Campbell, Peter T. Campbell, Geraldine Cancel-Tassin, Lisa Cannon-Albright, Daniele Campa, Neil Caporaso, Andre L. Carvalho, Andrew T. Chan, Jenny Chang-Claude, Stephen J. Chanock, Chu Chen, David C. Christiani, Kathleen B. M. Claes, Frank Claessens, Judith Clements, J. Margriet Collee, Marcia Cruz Correa, Fergus J. Couch, Angela Cox, Julie M. Cunningham, Cezary Cybulski, Kamila Czene, Mary B. Daly, Anna defazio, Peter Devilee, Orland Diez, Manuela Gago-Dominguez, Jenny L. Donovan, Thilo Doerk, Eric J. Duell, Alison M. Dunning, Miriam Dwek, Diana M. Eccles, Christopher K. Edlund, Digna R. Velez Edwards, Carolina Ellberg, D. Gareth Evans, Peter A. Fasching, Robert L. Ferris, Triantafillos Liloglou, Jane C. Figueiredo, Olivia Fletcher, Renee T. Fortner, Florentia Fostira, Silvia Franceschi, Eitan Friedman, Steven J. Gallinger, Patricia A. Ganz, Judy Garber, Jose A. Garcia-Saenz, Simon A. Gayther, Graham G. Giles, Andrew K. Godwin, Mark S. Goldberg, David E. Goldgar, Ellen L. Goode, Marc T. Goodman, Gary Goodman, Kjell Grankvist, Mark H. Greene, Henrik Gronberg, Jacek Gronwald, Pascal Guenel, Niclas Hakansson, Per Hall, Ute Hamann, Freddie C. Hamdy, Robert J. Hamilton, Jochen Hampe, Aage Haugen, Florian Heitz, Rolando Herrero, Peter Hillemanns, Michael Hoffmeister, Estrid Hogdall, Yun-Chul Hong, John L. Hopper, Richard Houlston, Peter J. Hulick, David J. Hunter, David G. Huntsman, Gregory Idos, Evgeny N. Imyanitov, Sue Ann Ingles, Claudine Isaacs, Anna Jakubowska, Paul James, Mark A. Jenkins, Mattias Johansson, Mikael Johansson, Esther M. John, Amit D. Joshi, Radka Kaneva, Beth Y. Karlan, Linda E. Kelemen, Tabea Kuhl, Kay-Tee Khaw, Elza Khusnutdinova, Adam S. Kibel, Lambertus A. Kiemeney, Jeri Kim, Susanne K. Kjaer, Julia A. Knight, Manolis Kogevinas, Zsofia Kote-Jarai, Stella Koutros, Vessela N. Kristensen, Jolanta Kupryjanczyk, Martin Lacko, Stephan Lam, Diether Lambrechts, Maria Teresa Landi, Philip Lazarus, Nhu D. Le, Eunjung Lee, Flavio Lejbkowicz, Heinz-Josef Lenz, Goska Leslie, Davor Lessel, Jenny Lester, Douglas A. Levine, Li Li, Christopher I. Li, Annika Lindblom, Noralane M. Lindor, Geoffrey Liu, Fotios Loupakis, Jan Lubinski, Lovise Maehle, Christiane Maier, Arto Mannermaa, Loic Le Marchand, Sara Margolin, Taymaa May, Lesley McGuffog, Alfons Meindl, Pooja Middha, Austin Miller, Roger L. Milne, Robert J. MacInnis, Francesmary Modugno, Marco Montagna, Victor Moreno, Kirsten B. Moysich, Lorelei Mucci, Kenneth Muir, Anna Marie Mulligan, Katherine L. Nathanson, David E. Neal, Andrew R. Ness, Susan L. Neuhausen, Heli Nevanlinna, Polly A. Newcomb, Lisa F. Newcomb, Finn Cilius Nielsen, Liene Nikitina-Zake, Borge G. Nordestgaard, Robert L. Nussbaum, Kenneth Offit, Edith Olah, Ali Amin Al Olama, Olufunmilayo I. Olopade, Andrew F. Olshan, Hakan Olsson, Ana Osorio, Hardev Pandha, Jong Y. Park, Nora Pashayan, Michael T. Parsons, Tanja Pejovic, Kathryn L. Penney, Wilbert H. M. Peters, Catherine M. Phelan, Amanda I. Phipps, Dijana Plaseska-Karanfilska, Miranda Pring, Darya Prokofyeva, Paolo Radice, Kari Stefansson, Susan J. Ramus, Leon Raskin, Gad Rennert, Hedy S. Rennert, Elizabeth J. van Rensburg, Marjorie J. Riggan, Harvey A. Risch, Angela Risch, Monique J. Roobol, Barry S. Rosenstein, Mary Anne Rossing, Kim De Ruyck, Emmanouil Saloustros, Dale P. Sandler, Elinor J. Sawyer, Matthew B. Schabath, Johanna Schleutker, Marjanka K. Schmidt, V. Wendy Setiawan, Hongbing Shen, Erin M. Siegel, Weiva Sieh, Christian F. Singer, Martha L. Slattery, Karina Dalsgaard Sorensen, Melissa C. Southey, Amanda B. Spurdle, Janet L. Stanford, Victoria L. Stevens, Sebastian Stintzing, Jennifer Stone, Karin Sundfeldt, Rebecca Sutphen, Anthony J. Swerdlow, Eloiza H. Tajara, Catherine M. Tangen, Adonina Tardon, Jack A. Taylor, M. Dawn Teare, Manuel R. Teixeira, Mary Beth Terry, Kathryn L. Terry, Stephen N. Thibodeau, Mads Thomassen, Line Bjorge, Marc Tischkowitz, Amanda E. Toland, Diana Torres, Paul A. Townsend, Ruth C. Travis, Nadine Tung, Shelley S. Tworoger, Cornelia M. Ulrich, Nawaid Usmani, Celine M. Vachon, Els Van Nieuwenhuysen, Ana Vega, Miguel Elias Aguado-Barrera, Qin Wang, Penelope M. Webb, Clarice R. Weinberg, Stephanie Weinstein, Mark C. Weissler, Jeffrey N. Weitzel, Catharine M. L. West, Emily White, Alice S. Whittemore, H-Erich Wichmann, Fredrik Wiklund, Robert Winqvist, Alicja Wolk, Penella Woll, Michael Woods, Anna H. Wu, Xifeng Wu, Drakoulis Yannoukakos, Wei Zheng, Shanbeh Zienolddiny, Argyrios Ziogas, Kristin K. Zorn, Jacqueline M. Lane, Richa Saxena, Duncan Thomas, Rayjean J. Hung, Brenda Diergaarde, James Mckay, Ulrike Peters, Li Hsu, Montserrat Garcia-Closas, Rosalind A. Eeles, Georgia Chenevix-Trench, Paul J. Brennan, Christopher A. Haiman, Jacques Simard, Douglas F. Easton, Stephen B. Gruber, Paul D. P. Pharoah, Alkes L. Price, Bogdan Pasaniuc, Christopher I. Amos, Peter Kraft, Sara Lindstrom

NATURE COMMUNICATIONS (2019)

Add to Collection

Article Oncology

Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery

Marlene Kranawetter, Beyhan Ataseven, Christoph Grimm, Stephanie Schneider, Stefan Riss, Pier Alesina, Sonia Prader, Martin K. Walz, Felix Harpain, Anton Stift, Florian Heitz, Alexander Reinthaller, Stephan Polterauer, Philipp Harter, Andreas du Bois

GYNECOLOGIC ONCOLOGY (2019)

Add to Collection

Article Oncology

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer-Impact for Diagnosis and Treatment Monitoring

Elena Ioana Braicu, Andreas du Bois, Jalid Sehouli, Julia Beck, Sonia Prader, Hagen Kulbe, Bernd Eiben, Philipp Harter, Alexander Traut, Klaus Pietzner, Ralf Glaubitz, Beyhan Ataseven, Radoslav Chekerov, Christoph Keck, Thomas Winkler, Sebastian Heikaus, Peggy Gellendin, Ekkehard Schuetz, Florian Heitz

Summary: This study demonstrates the use of low-coverage cell-free tumor DNA sequencing to detect chromosomal instability (CI) in ovarian cancer patients. The CI can serve as a reliable marker for ovarian cancer detection and is associated with prognostic and predictive clinical measures. The findings suggest that ctDNA analysis based on the CNI-Score can be an important tool for diagnostics and therapy monitoring in high-grade epithelial ovarian cancer.

CANCERS (2022)

Add to Collection

Article Oncology

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer

Florian Heitz, Beyhan Ataseven, Claudia Staniczok, Carsten Denkert, Kerstin Rhiem, Eric Hahnen, Sebastian Heikaus, Malak Moubarak, Julia Welz, Timoleon Dagres, Vasilios Vrentas, Mareike Bommert, Stephanie Schneider, Nicole Concin, Philipp Harter

Summary: Testing for HRD is crucial for recommending appropriate therapy in primary high-grade ovarian cancer patients. While patients with a BRCA mutation are defined as HRD deficient, approximately 20% of patients without BRCA mutation can still have HRD deficiency based on tumor genomic analysis. This study highlights the importance of obtaining sufficient tumor tissue and conducting additional BRCA germline testing to improve the accuracy of HRD testing and inform treatment decisions.

CANCERS (2023)

Add to Collection

Article Oncology

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients

Majdi Imterat, Philipp Harter, Kerstin Rhiem, Florian Heitz, Stephanie Schneider, Nicole Concin, Malak Moubarak, Julia Welz, Vasileios Vrentas, Alexander Traut, Eric Hahnen, Rita Schmutzler, Andreas du Bois, Beyhan Ataseven

Summary: Limited data is available on deleterious variants in genes other than BRCA1/2. A retrospective cohort study investigated the impact of germline mutations on ovarian cancer prognosis. The study found that germline mutations, including BRCA1/2 and other genes, were detected in a quarter of ovarian cancer patients and were associated with significantly better outcomes in terms of overall survival and progression-free survival.

CANCERS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.